ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Systemic lupus erythematosus (SLE)"

  • Abstract Number: 1280 • ACR Convergence 2024

    Abnormal Cortical Gyrification Patterns in Adolescents with Childhood-onset SLE: Early Associations with Perceived Fatigue

    Diana Valdes Cabrera1, Tala El Tal2, Santiago Arciniegas1, Oscar Mwizerwa3, Asha Jeyanathan3, Lawrence Ng1, Paris Moaf1, Joanna Law4, Sarah Mossad5, Birgit Ertl-Wagner1, Ann Yeh1, Helen Branson1, Adrienne Davis6, Linda Hiraki1, Deborah Levy1, Busi Zapparoli7, Ashley Danguecan8 and Andrea Knight9, 1The Hospital for Sick Children, Toronto, ON, Canada, 2The Hospital For Sick Children & Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 3The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, The Hospital for Sick Children, Neurosciences and Mental Health, Research Institute, Toronto, ON, Canada, 4The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 5Hospital for Sick Children, Toronto, ON, Canada, 6Division of Pediatric Emergency Medicine, Department of Pediatrics, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, 7The Hospital for Sick Children, Etobicoke, ON, Canada, 8The Hospital for Sick Children, Department of Psychology, University of Toronto, Toronto, ON, Canada, 9Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Fatigue and brain fog are early complaints in adolescents with childhood-onset SLE (cSLE), who experience disease onset during a critical period of brain development.…
  • Abstract Number: 1495 • ACR Convergence 2024

    Real-World Reduction in Disease Flares and Oral Corticosteroid Use with Anifrolumab Therapy in Systemic Lupus Erythematosus: A Claims-Based Study

    Mawuena Binka1, Rana Muhammad Qasim Khan2, Joseph Tkacz3, Donna McMorrow3, Laurence Gozalo3 and Gail Kerr4, 1BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, 2BioPharmaceuticals Medical, AstraZeneca, Wilmington, 3Inovalon, Bowie, MD, 4Veterans Affairs Medical Center, Georgetown and Howard University Hospitals, Washington, DC

    Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, chronic autoimmune disease characterized by frequent episodes of disease activity (flares) of varying severity.1 SLE flares are…
  • Abstract Number: 1511 • ACR Convergence 2024

    Lupus Nephritis and Response to Treatment in Latin America

    Rosana Quintana1, Romina Nieto2, Diana Carolina Fernández Ávila3, Rosa Serrano Morales4, Guillermina Harvey5, Lucia Hernandez6, Karen Roberts7, Marina Scolnik8, Carmen Funes Soaje9, Paula Alba10, Veronica Saurit11, Mercedes Garcia12, Guillermo Berbotto13, VERONICA BELLOMIO14, Wilfredo Patiño Grageda15, Graciela Gómez16, Cecilia Pisoni17, Ana Malvar18, Vicente Juarez19, Nilzio A. Da Silva20, ODIRLEI MONTICIELO21, Henrique Ataide Mariz22, Francinne Machado Ribeiro23, Eduardo Borba24, Luciana Parente24, Edgard Torres25, Oscar Neira26, Loreto Massardo27, Gustavo Aroca Martínez28, Carlos A. Cañas Davila29, Gerardo Quintana López30, Carlos Enrique Toro-Gutierrez31, Mario Moreno32, Andres Zuñiga33, Miguel Angel Saavedra Salinas34, Margarita Portela Hernandez35, Hilda Fragoso-Loyo36, Luis H. Silveira Torre37, Ignacio García De La Torre38, Carlos Abud Mendoza39, Marcos Fonseca Hernández40, Jorge Esquivel-Valerio41, Isabel Acosta Colman42, Jhonatan Losanto43, Claudia Selene Mora Trujillo44, Katiuzka Zuñiga Corrales45, Roberto Muñoz Louis46, Martin Rebella47, Álvaro Danza48 Manuel Ugarte-Gil49, Graciela Alarcon50, Urbano Sbarigia51, Federico Zazzetti52, Ashley Orillion53, Guillermo Pons-Estel54 and Bernardo Pons-Estel54, 1Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, 2Centro Regional de Enfermedades Autoinmunes y Reumaticas. GO-CREAR, Rosario, Santa Fe, Argentina, 3Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, Rosario, Argentina, 4Sanatorio Parque. Centro de Enfermedades Autoinmunes y Reumaticas del Grupo Oroao., Rosario, Argentina, 5Escuela de Estadística, Facultad de Ciencias Económicas y Estadística, Universidad Nacional de Rosario, Rosario, Argentina, Rosario, Argentina, 6Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), ROSARIO, Santa Fe, Argentina, 7Sección Reumatología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 8Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 9Hospital Italiano, Cordoba, Argentina, 10Hospital Cordoba, Cordoba, Spain, 11hospital privado universitario de cordoba, Córdoba, Argentina, 12HIGA San Martin, La Plata, Argentina, 13Unidad de Enfermedades Autoinmunes, Hospital Escuela Eva Perón, ROSARIO, Argentina, 14Hospital Padilla, San Miguel de Tucumán, Argentina, 15Hospital General de Agudos Dr Ramos Mejia, CABA, Argentina, 16Instituto de Investigaciones Médicas Alfredo Lanari, Autónoma de Buenos Aires, Argentina, 17CEMIC, Buenos Aires, Argentina, 18Organización Médica de Investigación, Buenos Aires, Argentina, 19Hospital Señor del Milagro, Salta, Salta, Argentina, 20Hospital das Clinicas, Universidad Federal de Goias, Goias, Goias, Brazil, 21HOSPITAL DE CLINICAS DE PORTO ALEGRE, PORTO ALEGRE, Rio Grande do Sul, Brazil, 22Universidad Federal de Pernambuco, Pernambuco, Brazil, 23Hospital Universitario Pedro Ernesto, UERJ, Rio De Janeiro, Brazil, Rio de Janeiro, Brazil, 24Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, 25Universidad Federal São Paulo, São Paulo, SP, Brazil, 26Hospital del Salvador, Santiago de Chile, Chile, 27Facultad de Medicina y Ciencia, Universidad San Sebastián, San Sebastián, Chile, 28Universidad Simón Bolivar, Barranquilla, Colombia, Barranquilla, Colombia, 29Fundación Valle del Lili, Unidad de Reumatología, Cali, Colombia, 30Universidad de Los Andes, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia, 31Reference Center for Osteoporosis & Rheumatology, Cali, Colombia, 32Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador, Guayaquil, Ecuador, 33Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador, 34División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, CDMX, Mexico, 35Departamento de Reumatología del Hospital de especialidades del Centro Médico Nacional Siglo XXI del Instituto Mexicano del Seguro Social (IMSS), Mexico, Mexico, 36Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, 37Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., Mexico City, Mexico, 38Depto. de Inmunología y Reumatología; Centro de Estudios de Investigación Básica y Clínica, Guadalajara, Mexico, 39Hospital Central Dr. Ignacio Morones Prieto, SLP, México, SLP, Mexico, 40Hospital Central Dr. Ignacio Morones Prieto, San Luis Potosí, Mexico, 41Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, MONTERREY, Mexico, 42Hospital de Clínicas I, Asunción, Paraguay, 43Hospital de Clínicas I, San Lorenzo, Paraguay, 44Hospital Nacional Edgardo Rebagliatti Martins, Lima, Peru, 45Hospital Cayetano Heredia. Universidad Peruana Cayetano Heredia, Lima, Peru, 46Hospital Docente Padre Billini, Santo Domingo, República Dominicana, Santo Domingo, Dominican Republic, 47Unidad Enfermedades Autoinmunes Sistemicas, Clinica Medica C-Hospital de Clinicas, UDELAR Montevideo, Montevideo, Uruguay, 48Médica Uruguaya Corporación de Asistencia Médica (MUCAM). Clínica Médica - Facultad de Medicina - UdelaR, Montevideo, Uruguay, 49Universidad Cientifica del Sur, Lima, Lima, Peru, 50The University of Alabama at Birmingham, Birmingham, AL, 51Johnson & Johnson Innovative Medicine, Brussels, Belgium, 52Johnson & Johnson Innovative Medicine, Horsham, PA, PA, 53Johnson & Johnson Innovative Medicine, Spring House, PA, PA, 54Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina

    Background/Purpose: The Latin American Group for the Study of Lupus (GLADEL) 2.0 is an observational prevalent and incident cohort of patients with systemic lupus erythematosus…
  • Abstract Number: 1528 • ACR Convergence 2024

    Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: National Inpatient Sample Analysis

    Maria Romero Noboa1, Almurtada Razok2, Husam El Sharu3 and Rafaella Litvin2, 1University of Alabama at Birmingham, Chicago, IL, 2John H Stroger Jr Hospital of Cook County, Chicago, IL, 3East Carolina University, Greenville, NC

    Background/Purpose: Systemic Lupus Erythematosus (SLE) can lead to a range of pulmonary complications, including Pulmonary Arterial Hypertension (PAH), which affects between 0.5% and 17.5% of…
  • Abstract Number: 1549 • ACR Convergence 2024

    Prescribing Trends for Novel Treatments in Systemic Lupus from 2017 to 2022

    Celestine He1, Zhonghan Li1, Sumanth Chennareddy2 and Chrisanna Dobrowolski3, 1Icahn School of Medicine, Mount Sinai, New York, NY, 2Icahn School of Medicine, New York, NY, 3Icahn School of Medicine at Mount Sinai, New York, NY

    Background/Purpose: Treatment of Systemic Lupus Erythematosus (SLE) has evolved substantially in the past decade. In 2011, the FDA approved belimumab, the first targeted monoclonal antibody…
  • Abstract Number: 1688 • ACR Convergence 2024

    Discovery and Validation of a New Classification of ANA-RMDs That Better Predict Long Term Outcomes Compared to Legacy Diagnoses

    Jack Arnold1, Lucy Carter1, Yuzaiful Yusof2, Zoe Wigston2, Daniel Toro Dominguez3, Samuel Relton4, Guillermo Barturen5, Marta Alarcon-Riquelme6 and Edward Vital7, and PRECISESADS consortium, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, United Kingdom, 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, England, United Kingdom, 3Centro Pfizer-Universidad de Granada-Junta de Andalucía de Genómica e Investigación Oncológica (GENYO), Granada, Andalucia, Spain, 4Leeds Institute of Data Analytics, University of Leeds, Leeds, UK, Leeds, England, United Kingdom, 5Center for Genomics and Oncological Research (GENYO), Andalusia, Spain, 6Fundación Progreso y Salud, Andalusian Government, Granada, Spain, 7Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom, Leeds, England, United Kingdom

    Background/Purpose: ANA-associated RMDs (ANA-RMDs) include SLE, Sjogren’s, Scleroderma, Myositis, and mixed/undifferentiated CTD. Despite overlapping clinical and immunophenotypic features, there is significant disparity in access to…
  • Abstract Number: 1780 • ACR Convergence 2024

    Next Generation Sequencing Analysis Reveals Complex Genetic Architecture of Childhood-onset Systemic Lupus Erythematosus

    Laura Lewandowski1, Linda Hiraki2, Christiaan Scott3, Ana Barrera-Vargas4, Diana Gómez-Martin5, Michael Ombrello6, Ivona Aksentijevich7, Zuoming deng8, Anthony Musolf9, Subrata Paul10, Dan Hupalo11, Clifton Dalgard11, Sarfaraz Hasni12, Earl Silverman13 and Mariana Kaplan14, 1NIAMS, NIH, Bethesda, MD, 2The Hospital for Sick Children, Toronto, ON, Canada, 3Pediatric Rheumatology, Children’s Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, 4Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Federal District, Mexico, 5INCMNSZ, Mexico, Distrito Federal, Mexico, 6National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), North Bethesda, MD, 7National Human Genome Research Institute, NIH, Bethesda, MD, 8National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD, 9Computational and Statistical Genomics Branch, NHGRI, NIH, Baltimore, MD, 10Collaborative Bioinformatics Resource, NIAID, NIH, Bethesda, MD, 11The American Genome Center, Department of Anatomy, Physiology & Genetics, Uniformed Services University, Bethesda, MD, 12National Institutes of Health, Bethesda, MD, 13Silverman, Toronto, ON, Canada, 14NIAMS/NIH, Bethesda, MD

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a potentially life-threatening autoimmune disease. Childhood-onset SLE (cSLE) patients have younger disease onset and more severe disease than adults,…
  • Abstract Number: 1800 • ACR Convergence 2024

    WWC1 Regulates Type I Interferon Production Through Modulation of cGAS-STING Signaling in Keratinocytes

    Bin Xu, Laura Cencer, Benjamin Klein, Shannon Loftus, Lam Tsoi, Johann Gudjonsson and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI

    Background/Purpose: Our recent study uncovered a role for dysregulation of the Hippo signaling pathway in systemic lupus erythematosus (SLE) keratinocytes (KCs) driven by overexpression of…
  • Abstract Number: 1893 • ACR Convergence 2024

    Hydroxychloroquine Use in Early Pregnancy and Risk of Preterm Delivery in a Californian Cohort of Lupus Pregnancy

    Amadeia Rector1, Emily Liu2, Miranda Cantu3, Eliza Chakravarty4, Maurice Druzin5, Gary Shaw6, Michael Weisman7, Monique Hedderson2 and Julia Simard8, 1Stanford University, San Francisco, CA, 2Kaiser Permanente Division of Research, Oakland, CA, 3Patient partner, Portage, MI, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Stanford University School of Medicine, Stanford, CA, 6Stanford University School of Medicine, Stanford, 7Stanford University, Los Angeles, CA, 8Stanford School of Medicine, Stanford, CA

    Background/Purpose: Preterm delivery (PTD) occurs 2-3 times more frequently in patients with systemic lupus erythematosus (SLE) compared to the general obstetric population. Hydroxychloroquine (HCQ), a…
  • Abstract Number: 2183 • ACR Convergence 2024

    Accuracy of AI Tools for Diagnosis of Connective Tissue Disease

    Indira Sriram1, Gabriel Tarshish2 and Megan Curran2, 1University of Colorado, Aurora, CO, 2Children's Hospital Colorado, Aurora, CO

    Background/Purpose: In this work, we study the ability of generative artificial intelligence (AI) based tools to diagnose pediatric rheumatological diseases. Specifically, we seek to answer…
  • Abstract Number: 2384 • ACR Convergence 2024

    Performance and Concordance of Two Different Methods of Detecting the Commonest Autoantibodies in Systemic Lupus Erythematosus

    Ranjan Gupta1, Sonam Rajput2, Rudra Prosad Goswami2, Jayanth Kumar2 and Amita Aggarwal3, 1All India Institute of Medical Sciences, New Delhi, Delhi, India, 2All India Institute of Medical Sciences, New Delhi, New Delhi, India, 3Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India

    Background/Purpose: Autoantibodies in SLE can be detected by either immunoblot assay or by ELISA. Both these methods may have variable performance with respect to the…
  • Abstract Number: 2403 • ACR Convergence 2024

    Health-related Quality of Life in Women with Systemic Lupus Erythematosus with Permanent Skin Damage and Its Association with Self-esteem and Symptoms of Depression and Anxiety – a Cross-sectional Study

    Fernando A Oliveira1, Fabiana Moura2, Ana Flávia Dias3, Claudia Santoro3, Fernando Pereira2, Rosa Telles2 and Cristina Lanna2, 1Faculdade de Ciências Médicas de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil, 2Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil, 3Grupo Santa Casa de Belo Horizonte, Belo Horizonte, Minas Gerais, Brazil

    Background/Purpose: Body image of systemic lupus erythematosus (SLE) patients is affected by the mucocutaneous manifestations and its scars, in particular related to discoid lupus. The…
  • Abstract Number: 2420 • ACR Convergence 2024

    Blood Transcriptome Analysis Reveals Enhanced B Cell and Complement Cascade Signatures in Patients with Major Neuropsychiatric Systemic Lupus Erythematosus

    Dionysis Nikolopoulos1, George Sentis2, Jason Kitsos2, Panagiotis Garantziotis3, Noemin Kapsala2, antigoni Pieta2, Myrto Nikoloudaki4, Theodora Manolakou5, Sofia Flouda2, Ioannis Parodis6, Anastasia Filia2, George Bertsias7, Antonis Fanouriakis2 and Dimitrios Boumpas8, 1Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, 2National and Kapodistrian University of Athens, Athens, Greece, 3Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany, Erlangen, Germany, 4Rheumatology and Clinical Immunology, University of Crete School of Medicine, Heraklion, Greece, Heraklion, Greece, 5Karolinska Institutet, Stockholm, Sweden, 6Karolinska Institutet, Karolinska University Hospital; Örebro University, Solna, Sweden, 7Laboratory of Rheumatology, Autoimmunity and Inflammation. University Hospital, Rheumatology, Clinical Immunology, Heraklion, Greece, 84th Department of Internal Medicine, "Attikon" University Hospital, Athens, Greece, Athens, Greece

    Background/Purpose: The molecular basis of neuropsychiatric systemic lupus erythematosus (NPSLE) remains elusive because of clinical heterogenicity, the complexity of pathophysiologic mechanisms involved and limited access…
  • Abstract Number: 2437 • ACR Convergence 2024

    Aryl Hydrocarbon Receptor as an Intrinsic Novel Checkpoint That Inhibits TLR7-induced B-cell Activation in SLE

    Changming Lu1, Jose Rubio2, Hui-Chen Hsu1 and John D. Mountz3, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Hoover, AL, 3University Alabama Birmingham, Birmingham, AL

    Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by an increase in T-bet+ IgD−CD27− double negative 2 (DN2) B cells, attributed to heightened TLR7 signaling. Identifying…
  • Abstract Number: 2600 • ACR Convergence 2024

    Repression of the Aryl-hydrocarbon Receptor Prevents Oxidative Stress and Ferroptosis of Intestinal γδT Cells and Alleviates Systemic Lupus Erythematosus

    Qiaolin Wang1, Yutong Wu2, Qianjin Lu1 and Ming Zhao1, 1Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China (People's Republic), 2Department of Dermatology, Hunan Key Laboratory of Medical Epigenomics, Second Xiangya Hospital, Central South University, Nanjing, China (People's Republic)

    Background/Purpose: Dysregulation of intestinal γδT cells orchestrates the pathogenesis of various autoimmune disorders, however, its involvement in systemic lupus erythematosus (SLE) etiology remains elusive.Methods: Employing single-cell sequencing, we…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 150
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology